MY173582A - Extended-release formulation for reducing the frequency of urination and method of use thereof - Google Patents

Extended-release formulation for reducing the frequency of urination and method of use thereof

Info

Publication number
MY173582A
MY173582A MYPI2014701369A MYPI2014701369A MY173582A MY 173582 A MY173582 A MY 173582A MY PI2014701369 A MYPI2014701369 A MY PI2014701369A MY PI2014701369 A MYPI2014701369 A MY PI2014701369A MY 173582 A MY173582 A MY 173582A
Authority
MY
Malaysia
Prior art keywords
extended
urination
frequency
reducing
release formulation
Prior art date
Application number
MYPI2014701369A
Other languages
English (en)
Inventor
David A Dill
Original Assignee
Wellesley Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/343,332 external-priority patent/US20120135050A1/en
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by Wellesley Pharmaceuticals Llc filed Critical Wellesley Pharmaceuticals Llc
Publication of MY173582A publication Critical patent/MY173582A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Power-Operated Mechanisms For Wings (AREA)
  • Guiding Agricultural Machines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
MYPI2014701369A 2012-01-04 2012-08-22 Extended-release formulation for reducing the frequency of urination and method of use thereof MY173582A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/343,332 US20120135050A1 (en) 2010-07-08 2012-01-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof

Publications (1)

Publication Number Publication Date
MY173582A true MY173582A (en) 2020-02-04

Family

ID=48745355

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014701369A MY173582A (en) 2012-01-04 2012-08-22 Extended-release formulation for reducing the frequency of urination and method of use thereof

Country Status (13)

Country Link
US (3) US8685453B2 (enExample)
JP (4) JP2015503583A (enExample)
KR (2) KR20180025993A (enExample)
AU (2) AU2012363789B2 (enExample)
BR (1) BR112014016661A8 (enExample)
CA (1) CA2856677A1 (enExample)
IL (1) IL232715A0 (enExample)
MX (1) MX2014008283A (enExample)
MY (1) MY173582A (enExample)
RU (1) RU2603471C2 (enExample)
SG (1) SG11201500407XA (enExample)
WO (1) WO2013103390A1 (enExample)
ZA (1) ZA201404606B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532959B2 (en) 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
CN103796669B (zh) 2011-07-18 2016-11-09 重症监护诊断股份有限公司 治疗心血管疾病和预测运动疗法功效的方法
CA2868073C (en) * 2012-03-30 2020-12-29 Givaudan S.A. N-acyl proline derivatives as food flavouring compounds
RU2016152226A (ru) * 2014-06-06 2018-07-09 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения
EP3197441A4 (en) * 2014-09-24 2018-05-23 Wellesley Pharmaceuticals, LLC Pharmaceutical formulation for reducing bladder spasms and method of use thereof
JP2018526441A (ja) * 2015-09-01 2018-09-13 ウェルズリー ファーマスーティカルズ、エルエルシー 延長、遅延および即時放出製剤、ならびにその製造および使用方法
EP3344241A4 (en) * 2015-09-01 2019-04-03 Wellesley Pharmaceuticals, LLC FORMULATIONS WITH DELAYED RELEASE, METHOD FOR THE PRODUCTION AND USE THEREOF
SG11201805527QA (en) * 2015-09-30 2018-07-30 Wellesley Pharmaceuticals Llc Composition for reducing the frequency of urination, method of making and use thereof
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
JP7229012B2 (ja) * 2018-12-25 2023-02-27 小林製薬株式会社 内服用医薬組成物
JP2019069991A (ja) * 2018-12-27 2019-05-09 ウェルズリー ファーマスーティカルズ、エルエルシー 膀胱痙攣を低減するための医薬製剤およびその使用の方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE169498T1 (de) * 1991-09-06 1998-08-15 Mcneilab Inc Zusammensetzung, die eine tramadol-verbindung und acetaminophen enthält, und ihre verwendung
AU6747698A (en) * 1997-04-11 1998-11-11 Nippon Shinyaku Co. Ltd. Remedies for frequent urination and urinary incontinence
US7138393B2 (en) * 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
JP3660979B2 (ja) * 2000-09-05 2005-06-15 国立大学法人金沢大学 夜間頻尿症の治療剤、夜間頻尿症の予防剤
RU2193401C1 (ru) * 2001-04-02 2002-11-27 Аль-Шукри Салман Хасунович Способ лечения гиперактивности мочевого пузыря
JPWO2003043655A1 (ja) * 2001-11-19 2005-03-10 小野薬品工業株式会社 頻尿の治療剤
CN1633283A (zh) * 2002-02-19 2005-06-29 法玛西雅公司 环加氧酶抑制剂和抗蕈毒碱试剂用于治疗失禁的用途
US7582651B2 (en) * 2002-07-11 2009-09-01 Takeda Pharmaceutical Company Limited Pyrrolopyridine derivative and use thereof
KR100522239B1 (ko) * 2002-07-16 2005-10-18 주식회사 서울제약 아세트아미노펜을 함유하는 제어방출성의 경구용 제제
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
WO2004026308A1 (en) * 2002-09-21 2004-04-01 Shuyi Zhang Sustained release compound of acetamidophenol and tramadol
DK1492519T3 (da) * 2003-03-21 2007-03-05 Dynogen Pharmaceuticals Inc Fremgangsmåder til behandling af lidelser i den nedre urinvej ved anvendelse af alfa-2-delta-underenhedscalciumkanalsmodulatorer med glat muskel-modulatorer
US20040186180A1 (en) * 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
DE10356112A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
WO2006059237A1 (en) * 2004-08-30 2006-06-08 Lunamed, Inc. 4-phenylbutyric acid controlled-release formulations for therapeutic use
EP1879578A4 (en) * 2005-03-21 2009-05-13 Dov Pharmaceutical Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE
EP1871372A4 (en) * 2005-04-08 2010-06-02 Neuromed Pharmaceuticals Ltd COMBINATION THERAPY WHICH INCLUDES AN AGENT BLOCKING CALCIUM CHANNELS OF TYPE N FOR THE RELIEF OF PAIN
EA200800370A1 (ru) * 2005-07-20 2008-06-30 Панацея Биотек Лтд. Новая фармацевтическая лекарственная форма ингибитора фермента циклооксигеназы с модифицированным высвобождением
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
US20080166407A1 (en) 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2007072503A2 (en) * 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
US20070237816A1 (en) * 2006-04-06 2007-10-11 David Finkelstein Acetaminophen formulation for joint pain relief
BRPI0714915A2 (pt) 2006-07-28 2013-05-28 Reddys Lab Ltd Dr composiÇço farmacÊuticas; formas de dosagem farmacÊutica; e processo para o preparo de uma composiÇço farmacÊutica
US20080057122A1 (en) * 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
EP2630955B1 (en) * 2007-08-15 2021-09-22 Johnson & Johnson Consumer Inc. Immediate release and sustained release ibuprofen dosing regimen
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
JP2018016869A (ja) * 2016-07-29 2018-02-01 日立化成株式会社 アルミニウム系多孔質体及びその製造方法

Also Published As

Publication number Publication date
MX2014008283A (es) 2015-03-03
JP2015503583A (ja) 2015-02-02
ZA201404606B (en) 2015-11-25
AU2017203418A1 (en) 2017-06-08
AU2012363789A1 (en) 2014-07-17
CA2856677A1 (en) 2013-07-11
BR112014016661A8 (pt) 2017-07-04
IL232715A0 (en) 2014-07-31
US20140154320A1 (en) 2014-06-05
BR112014016661A2 (pt) 2017-06-13
NZ721818A (en) 2017-07-28
US8685453B2 (en) 2014-04-01
NZ732149A (en) 2018-11-30
AU2012363789A2 (en) 2014-07-24
US20130216620A1 (en) 2013-08-22
JP2018087217A (ja) 2018-06-07
KR20140108675A (ko) 2014-09-12
AU2017203418B2 (en) 2019-01-17
JP2017031172A (ja) 2017-02-09
NZ626619A (en) 2017-03-31
SG11201500407XA (en) 2015-03-30
JP2020037575A (ja) 2020-03-12
KR20180025993A (ko) 2018-03-09
US20150272968A1 (en) 2015-10-01
RU2014131285A (ru) 2016-02-20
AU2012363789B2 (en) 2017-04-13
RU2603471C2 (ru) 2016-11-27
WO2013103390A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
MY173582A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ630471A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
MX2014008284A (es) Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta.
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
MY173215A (en) Acetylcysteine compositions and methods of use thereof
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
NZ702799A (en) Methods and compositions for cns delivery of arylsulfatase a
PH12014502516A1 (en) Formulations and methods for vaginal delivery of antiprogestins
WO2012145575A3 (en) Therapy for leukemia
IN2014MN02269A (enExample)
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
MX357704B (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
MX2015010594A (es) Esteres de testosterona de cadena larga lipobalanceados para suministro oral.
IN2014DN10134A (enExample)
PH12015500070A1 (en) Pediatric oral liquid compositions containing nepadutant
PH22011000655U1 (en) Pharmaceutical herbal composition
UA60688U (ru) Фармацевтическая композиция для лечения заболеваний органов дыхания и заболеваний аллергического типа
AR063816A1 (es) Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion
IN2013MU02111A (enExample)
HRP20120600T1 (hr) Endipalenske formulacije u liječenju psorijaze
PH22011000489U3 (en) Solid pharmaceutical herbal compositions
IN2013MU02110A (enExample)
UA61103U (ru) Фармацевтическая композиция для лечения множественно-резистентных форм туберкулеза
UA59175U (ru) Способ медицинской реабилитации больных синдромом повышенной утомляемости